Literature DB >> 25762878

Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Chasity M Shelton1, Elizabeth L Alford1, Stephanie Storgion2, James Wheless3, Stephanie J Phelps4.   

Abstract

We describe the use of topiramate in a healthy 12-year-old (88-kg) male who developed refractory generalized convulsive status epilepticus. Seizures persisted despite aggressive use of benzodiazepines (intravenous lorazepam; oral clorazepate), barbiturates (i.e., phenobarbital, pentobarbital), and hydantoins. The child's seizures were controlled with nasogastrically administered topiramate in doses up to 500 mg twice daily (11.4 mg/kg/day). The patient did not display any clinical or laboratory signs of metabolic acidosis while receiving topiramate. Topiramate should be considered as a treatment option in refractory status epilepticus.

Entities:  

Keywords:  epilepsy; pediatric; refractory status epilepticus; topiramate; treatment

Year:  2014        PMID: 25762878      PMCID: PMC4341418          DOI: 10.5863/1551-6776-19.4.317

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  29 in total

1.  Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons.

Authors:  R J DeLorenzo; S Sombati; D A Coulter
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

2.  Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate.

Authors:  X Zhang; A A Velumian; O T Jones; P L Carlen
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

Review 3.  The use of topiramate in refractory status epilepticus.

Authors:  A R Towne; L K Garnett; E J Waterhouse; L D Morton; R J DeLorenzo
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

4.  Topiramate and metabolic acidosis in pediatric epilepsy.

Authors:  M Takeoka; G L Holmes; E Thiele; B F Bourgeois; S L Helmers; F H Duffy; J J Riviello
Journal:  Epilepsia       Date:  2001-03       Impact factor: 5.864

Review 5.  Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.

Authors:  H S White
Journal:  Epilepsia       Date:  1999       Impact factor: 5.864

6.  Pediatric refractory partial status epilepticus responsive to topiramate.

Authors:  Lubov Blumkin; Tally Lerman-Sagie; Tzion Houri; Eli Gilad; Andrea Nissenkorn; Mira Ginsberg; Nathan Watemberg
Journal:  J Child Neurol       Date:  2005-03       Impact factor: 1.987

7.  Clinical effects and toxicokinetic evaluation following massive topiramate ingestion.

Authors:  Michael J Lynch; Anthony F Pizon; Mohamed G Siam; Matthew D Krasowski
Journal:  J Med Toxicol       Date:  2010-06

8.  Topiramate as an inhibitor of carbonic anhydrase isoenzymes.

Authors:  S J Dodgson; R P Shank; B E Maryanoff
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

9.  Aborted and refractory status epilepticus in children: a comparative analysis.

Authors:  Florise A C P Lambrechtsen; Jeffrey R Buchhalter
Journal:  Epilepsia       Date:  2007-12-18       Impact factor: 5.864

10.  Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy.

Authors:  Jakob Christensen; Frederik Andreasen; Jørgen Hjelm Poulsen; Mogens Dam
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.